$14.10
0.62 (+4.60%)
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
CAPS Rating:
A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.
Recs
good pipeline, Coming FDA approval, no debt, 158 million in cash, possible buy-out